Disposition of 100000 shares by Jon Stonehouse of BioCryst Pharmaceuticals at 10.38 subject to Rule 16b-3

BCRX Stock  USD 7.60  0.11  1.47%   
Slightly above 66 percent of all BioCryst Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that a large number of traders are confidant. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by BioCryst Pharmaceuticals Director, Officer President Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 100000 common stock at 10.38 of BioCryst Pharmaceuticals by Jon Stonehouse on 24th of September 2024. This event was filed by BioCryst Pharmaceuticals with SEC on 2023-02-01. Statement of changes in beneficial ownership - SEC Form 4. Jon Stonehouse currently serves as ceo and president and executive director of BioCryst Pharmaceuticals

Cash Flow Correlation

BioCryst Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the BioCryst Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

BioCryst Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards BioCryst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

BioCryst Pharmaceuticals Fundamental Analysis

We analyze BioCryst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Flow From Operations

Cash Flow From Operations Comparative Analysis

BioCryst Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

BioCryst Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioCryst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

BioCryst Pharmaceuticals Related Equities

APLSApellis Pharmaceuticals   10.88   
0%
61.0%
ATRAAtara Biotherapeutics   8.11   
0%
45.0%
MDGLMadrigal Pharmaceuticals   5.53   
0%
31.0%
MCRBSeres Therapeutics   5.48   
0%
30.0%
PIRSPieris Pharmaceuticals   5.27   
0%
29.0%
DAWNDay One   2.85   
0%
16.0%
INMBINmune Bio   2.31   
0%
13.0%
TGTXTG Therapeutics   1.51   
0%
8.0%
AVXLAnavex Life   1.00   
0%
5.0%
AXSMAxsome Therapeutics   0.50   
0%
2.0%
IMUXImmunic   0.90   
5.0%
0%
KZRKezar Life   1.57   
8.0%
0%
VKTXViking Therapeutics   1.83   
10.0%
0%
BIVIBiovie   1.93   
10.0%
0%
CGTXCognition Therapeutics   2.27   
12.0%
0%
BPMCBlueprint Medicines   2.56   
14.0%
0%
PDSBPDS Biotechnology   5.00   
28.0%
0%
XFORX4 Pharmaceuticals   8.11   
45.0%
0%
SAVACassava Sciences   17.71   
100.0%
0%

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.